Online inquiry

IVTScrip™ mRNA-Human AKR1C1, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK19575MR)

This product GTTS-WK19575MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the AKR1C1 protein. This product can be used in Acinar cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_001353.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 1645
UniProt ID Q04828
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human AKR1C1, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK19575MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK28753MR IVTScrip™ mRNA-Human ATG12, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ATG12
GTTS-WK5172MR IVTScrip™ mRNA-Human CD292, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD292
GTTS-WK6544MR IVTScrip™ mRNA-Human AID, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AID
GTTS-WK28383MR IVTScrip™ mRNA-Human ARSA, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARSA
GTTS-WK1523MR IVTScrip™ mRNA-Human GS, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GS
GTTS-WK24922MR IVTScrip™ mRNA-Human APOBEC3F, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA APOBEC3F
GTTS-WK24596MR IVTScrip™ mRNA-Human ATP5C1, (Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ATP5C1
GTTS-WK10324MR IVTScrip™ mRNA-Human Acetylcholinesterase, (Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Acetylcholinesterase
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW